PDF(Pubmed)
Abstract：
(1) Background: Metastasis is a complex process in which the primary cancer cells spread to a distant organ or organs, creating a secondary tumor location, which in many patients leads to treatment failure and death. The aim of the present study was to assess the association of endothelial markers (i.e., sP-selectin, sE-selectin and von Willebrand factor) with the leptin-to-adiponectin ratio (LAR) and to perform an analysis of the predictive value on the survival of patients with luminal A and B invasive breast cancer (IBrC). (2) Methods: The trial included 70 treatment-naïve early-stage IBrC patients with a median age of 54.5 years and a median tumor diameter of 1.5 cm. The median duration of follow-up was 5.7 years, with a relapse rate of 15.71%. Specific immunoenzymatic kits were used to determine pre- and post-treatment concentrations of analyzed factors. (3) Results: Regardless of the treatment pattern, endothelial marker concentrations and the LAR increased after adjuvant treatment. The follow-up showed a significantly higher relapse rate in patients with IBrC who had higher pre-treatment sP-selectin and post-treatment LAR levels. According to receiver operating characteristic (ROC) analysis, a post-treatment LAR with a sensitivity of 88.9% and specificity of 57.9% discriminating cases with or without disease relapse. Additionally, a higher risk of breast cancer relapse was associated with a lower post-treatment sP-selectin concentration. (4) Conclusions: Our results showed mainly that pre-treatment sP-selectin levels and post-treatment LAR may have value as prognostic indicators and may contribute to predicting the future outcomes in patients with early-stage IBrC.
摘要：
（1）背景：转移是一个复杂的过程，其中原发性癌细胞扩散到远处的器官或器官，创建一个继发性肿瘤位置，这在许多患者中导致治疗失败和死亡。本研究的目的是评估内皮标志物(即，sP-选择素,sE-选择素和vonWillebrand因子)与瘦素与脂联素比值(LAR),并进行对腔内A和B浸润性乳腺癌(IBrC)患者生存的预测价值分析。（2）方法：该试验包括70例初治早期IBRC患者，中位年龄为54.5岁，中位肿瘤直径为1.5cm。中位随访时间为5.7年，复发率为15.71%。使用特异性免疫酶试剂盒来确定所分析因子的处理前和后处理浓度。（3）结果：无论治疗模式如何，辅助治疗后内皮标记物浓度和LAR升高.随访显示，治疗前sP-选择素和治疗后LAR水平较高的IBrC患者复发率明显较高。根据接收机工作特性(ROC)分析,治疗后LAR的敏感性为88.9%，特异性为57.9%，可区分是否有疾病复发的病例。此外,乳腺癌复发风险较高与治疗后sP-选择素浓度较低相关.（4）结论：我们的结果表明，治疗前sP-选择素水平和治疗后LAR可能具有预后指标的价值，并可能有助于预测早期IBRC患者的未来结局。
